Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
NCT04697576
Recruiting
This phase I trial investigates the effects of influenza vaccine in treating patients with stage I-IV melanoma. While intramuscular administration of influenza vaccine provides immunization against the influenza virus, giving influenza vaccine directly into the tumor (intralesional) may decrease the size of the injected melanoma tumor, or the extent of the melanoma within the body.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
07/28/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage IIA Cutaneous Melanoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8, Clinical Stage IIC Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma
Register for Updates
Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT02518555
Active Not Recruiting
This randomized phase II trial studies how well ibrutinib works when given together with vaccine therapies in treating patients without clinical signs or indications that raise the possibility of a particular disorder or dysfunction (asymptomatic) who have high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Vaccines, such as pneumococcal 13-valent conjugate vaccine, trivalent i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Register for Updates
Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT01351896
Active Not Recruiting
This phase II trial studies the effect of lenalidomide and vaccine in treating patients with early-stage asymptomatic chronic lymphocytic leukemia or small lymphocytic lymphoma. Lenalidomide may stop the growth of cancer cells by blocking blood flow to the cancer. It may also stimulate the immune system in different ways and stop cancer cells from growing. Vaccines may help the body build an effective immune response to kill cancer cells. Giving lenalidomide together with vaccine therapy may mak... Read More
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
05/07/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Ann Arbor Stage I Small Lymphocytic Lymphoma, Ann Arbor Stage II Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia With Unmutated Immunoglobulin Heavy Chain Variable-Region Gene, Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable-Region Gene, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Register for Updates
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living with HIV on Suppressive Antiretroviral Therapy
NCT04985760
Active Not Recruiting
Trimer 4571 is a vaccine designed to stimulate the development of broadly neutralizing antibodies (bnAbs) against HIV. Trimer 4571 is investigational, meaning it is not approved by the US Food and Drug Administration (FDA). There is limited human experience with the Trimer 4571 vaccine administered with aluminum hydroxide (alum) and the vaccine has not been tested in people with HIV prior to this study although it has been tested in healthy volunteers. The goal of this study is to see if Trimer... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: AIDS Clinical Trials Unit/The Ohio State University, Columbus, Ohio +1 locations
Conditions: HIV Infections
Register for Updates
Anti-pneumococcal Vaccine Strategy in Patients with Chronic Lymphocytic Leukemia
NCT05417165
Recruiting
This phase II trial compares the effect of initial vaccination (PCV20 followed by PSV23) with yearly vaccinations of PSV23 to the standard 5 year vaccination in patients with chronic lymphocytic leukemia. At present chronic lymphocytic leukemia patients are poorly protected by anti-pneumococcal vaccination. Current vaccination schedule for chronic lymphocytic leukemia patients is based on general recommendations in immunocompromised patients (initial vaccination with PCV13 followed by one dose o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/27/2024
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Register for Updates
Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
NCT01376505
Completed
This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with metastatic solid tumors. Vaccines made from antibodies and peptides combined with tumor cells may help the body build an effective immune response to kill tumor cells.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/13/2023
Locations: Ohio State University Medical Center, Columbus, Ohio
Conditions: Malignant Solid Tumour, Breast Cancer, Malignant Tumor of Colon, GIST, Ovarian Cancer
Register for Updates
Immune Responses to the Flu Shot During Pregnancy
NCT02148874
Completed
This study will examine effects of everyday life stress and obesity on immune responses to influenza virus vaccine (the flu shot) during pregnancy. Following vaccination, antibody levels against influenza (the flu) increase. Higher antibody levels indicate better immune protection from influenza. In addition to providing protection from the flu for yourself, being vaccinated during pregnancy may protect your baby from the flu during the first six months of life during which time infants cannot b... Read More
Gender:
FEMALE
Ages:
Between 18 years and 42 years
Trial Updated:
09/16/2019
Locations: The Ohio State University Wexner Medical Center, Columbus, Ohio
Conditions: Pregnancy
Register for Updates
Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA)
NCT00217373
Completed
This phase I trial is studying the side effects and best dose of interferon alfa-2b when given together with vaccine therapy and GM-CSF in treating patients with locally advanced or metastatic cancer that makes CEA. Vaccines made from a gene-modified virus may help the body build an effective immune response to kill cancer cells that make carcinoembryonic antigen (CEA). Biological therapies, such as GM-CSF, may stimulate the immune system in different ways and stop cancer cells from growing. Int... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2015
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Adult Solid Neoplasm
Register for Updates
FLUAD vs. FLUZONE HD Influenza Vaccine in Residents of Long Term Care
NCT03694808
Completed
Adjuvanted flu vaccine, Fluad, is not immunologically inferior to HD influenza vaccine in older persons living in long-term care.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
04/26/2024
Locations: Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio +1 locations
Conditions: Flu
Register for Updates
A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047
NCT03160339
Terminated
PXVX0047 (Adenovirus Type 4 and Type 7 Vaccine \[A549 Cells\], Live, Oral) is an investigational vaccine in development for the indication of active immunization against adenovirus infection. The primary goals of this Phase 1 study are to evaluate safety, pharmacodynamics (viral shedding), and immunogenicity of PXVX0047.
Gender:
ALL
Ages:
Between 18 years and 35 years
Trial Updated:
03/14/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio +1 locations
Conditions: Adenoviral Infection
Register for Updates
Type I-Polarized Autologous Dendritic Cell Vaccine With Tumor Blood Vessel Antigen-Derived Peptides in Metastatic Breast Cancer Patients
NCT02479230
Completed
This pilot clinical trial studies the safety of a dendritic cell vaccine when given with gemcitabine hydrochloride in treating patients with breast cancer that has spread beyond the breast and local lymph nodes to other organs in the body. The vaccine is made up of natural cells found in the blood, called dendritic cells, and peptides, or small fragments of protein which are loaded onto the dendritic cells. This combination may help activate the immune system against stromal cells, which are cel... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2022
Locations: University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio +1 locations
Conditions: Breast Cancer, Metastatic Breast Cancer
Register for Updates
Safety and Immunogenicity of a Nipah Virus Vaccine
NCT04199169
Completed
A first-in-human, phase 1 trial is to be conducted in a healthy adult population in the US to assess the safety and immunogenicity of three ascending Nipah vaccine (HeV-sG-V; Hendra virus soluble glycoprotein vaccine) dosages. Different dosing regimens and number of doses will also be explored.
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
11/16/2022
Locations: Cincinnati Children's Hospital Medical Center (CCHMC), Cincinnati, Ohio
Conditions: Nipah Virus Infection
Register for Updates